Kurzfassung

A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of VX 445 Comination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)